ALX Oncology

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, ALX Oncology sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 2 completed early-phase tilt top decile by trial count

ALX Oncology: 9 sponsored US clinical trials, 2 recruiting.

ALX Oncology sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Cancer, with 3 trials.

Top-decile sponsor footprint

ALX Oncology ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

NCT07085091
RECRUITING Phase 1

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

NCT07007559
ACTIVE NOT RECRUITING Phase 2

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127
ACTIVE NOT RECRUITING Phase 2

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333
ACTIVE NOT RECRUITING Phase 2

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294
COMPLETED Phase 1

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

NCT05524545
TERMINATED Phase 1

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

NCT04755244
TERMINATED Phase 1

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

NCT04417517
COMPLETED Phase 1

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

NCT03013218

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Therapeutic Areas

Head and Neck Cancer 3
Head and Neck Squamous Cell Carcinoma 2
NSCLC (Advanced Non-small Cell Lung Cancer) 1
CRC, Colorectal Cancer 1
Esophageal Squamous Cell Carcinoma (ESCC) 1
ESCC 1
Non-Hodgkin Lymphoma 1
Gastric Cancer 1
HNSCC 1
Gastric Adenocarcinoma 1

What is open in the ALX Oncology pipeline

2 recruiting of 9 indexed (22% open); 2 completed (22%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Head and Neck Cancer (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

ALX Oncology: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

ALX Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share ALX Oncology4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce BiosciencesHarvard University Faculty of Medicine
ALX Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ALX Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ALX Oncology page

9 registered trials is a research-attention snapshot, not an endorsement of ALX Oncology or any single study.

  • 2 of ALX Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Head and Neck Cancer is the condition ALX Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ALX Oncology pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.